AC006486.9 | Uncharacterized protein | | | | | | Tissue enhanced |
ADRA2C | Adrenoceptor alpha 2C | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
ALDH1A2 | Aldehyde dehydrogenase 1 family, member A2 | Enzymes
| | | | | Tissue enhanced |
AP000349.1 | Uncharacterized protein | | | | | | Tissue enhanced |
ASIC2 | Acid-sensing (proton-gated) ion channel 2 | Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
C1orf186 | Chromosome 1 open reading frame 186 | Predicted membrane proteins
| | | | | Tissue enhanced |
C1orf64 | Chromosome 1 open reading frame 64 | | | | | | Tissue enhanced |
C1QTNF6 | C1q and tumor necrosis factor related protein 6 | | | | | | Tissue enhanced |
CCDC171 | Coiled-coil domain containing 171 | | | | | | Tissue enhanced |
CDH13 | Cadherin 13 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CHURC1-FNTB | CHURC1-FNTB readthrough | | | | | | Tissue enhanced |
CYP24A1 | Cytochrome P450, family 24, subfamily A, polypeptide 1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets
| | | | | Tissue enhanced |
DPP6 | Dipeptidyl-peptidase 6 | Disease related genes Enzymes Potential drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
EMX2 | Empty spiracles homeobox 2 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
ESR1 | Estrogen receptor 1 | Cancer-related genes Disease related genes FDA approved drug targets Nuclear receptors Transcription factors
| | | | | Tissue enhanced |
FAP | Fibroblast activation protein, alpha | Cancer-related genes Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
FREM1 | FRAS1 related extracellular matrix 1 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
GABRP | Gamma-aminobutyric acid (GABA) A receptor, pi | FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
GAS1 | Growth arrest-specific 1 | Cancer-related genes Predicted secreted proteins
| | | | | Tissue enhanced |
GDF7 | Growth differentiation factor 7 | Predicted secreted proteins
| | | | | Tissue enhanced |
GLI1 | GLI family zinc finger 1 | Transcription factors
| | | | | Tissue enhanced |
HOXA10 | Homeobox A10 | Transcription factors
| | | | | Tissue enhanced |
HOXA11 | Homeobox A11 | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
HOXD10 | Homeobox D10 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
HOXD3 | Homeobox D3 | Transcription factors
| | | | | Tissue enhanced |
HOXD4 | Homeobox D4 | Transcription factors
| | | | | Tissue enhanced |
HOXD9 | Homeobox D9 | Transcription factors
| | | | | Tissue enhanced |
HTR1E | 5-hydroxytryptamine (serotonin) receptor 1E, G protein-coupled | G-protein coupled receptors Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
HTR2B | 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
IL17C | Interleukin 17C | Predicted secreted proteins
| | | | | Tissue enhanced |
KCNAB3 | Potassium voltage-gated channel, shaker-related subfamily, beta member 3 | | | | | | Tissue enhanced |
KCNG1 | Potassium voltage-gated channel, subfamily G, member 1 | Predicted membrane proteins Voltage-gated ion channels
| | | | | Tissue enhanced |
KIAA1199 | KIAA1199 | Enzymes Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
KLHL13 | Kelch-like family member 13 | | | | | | Tissue enhanced |
LEFTY2 | Left-right determination factor 2 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |
LIMS3L | LIM and senescent cell antigen-like domains 3-like | | | | | | Tissue enhanced |
LINGO2 | Leucine rich repeat and Ig domain containing 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
LONRF2 | LON peptidase N-terminal domain and ring finger 2 | | | | | | Tissue enhanced |
MEIS3 | Meis homeobox 3 | Predicted secreted proteins Transcription factors
| | | | | Tissue enhanced |
MMP3 | Matrix metallopeptidase 3 (stromelysin 1, progelatinase) | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
MSX1 | Msh homeobox 1 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
MUC16 | Mucin 16, cell surface associated | Predicted membrane proteins
| | | | | Tissue enhanced |
NPAS4 | Neuronal PAS domain protein 4 | Transcription factors
| | | | | Tissue enhanced |
OSR2 | Odd-skipped related transciption factor 2 | Transcription factors
| | | | | Tissue enhanced |
PAMR1 | Peptidase domain containing associated with muscle regeneration 1 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
PLK5 | Polo-like kinase 5 | Enzymes
| | | | | Tissue enhanced |
PTGFR | Prostaglandin F receptor (FP) | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
RP1-170O19.20 | Uncharacterized protein | | | | | | Tissue enhanced |
RPRM | Reprimo, TP53 dependent G2 arrest mediator candidate | Predicted membrane proteins
| | | | | Tissue enhanced |
RSPO1 | R-spondin 1 | Disease related genes Predicted secreted proteins
| | | | | Tissue enhanced |